IDYA ideayabio.com: Enterprise Value to EBITDA Ratio

IDEAYA Biosciences is developing targeted cancer therapies through strategic alliances with major pharmaceutical behemoths. The enterprise value to EBITDA multiple on the GURU.Markets chart demonstrates a trend where the current level equals 0.00. Despite growing demand in the synthetic lethality segment, the company faces research expenses and the risks associated with a lack of revenue.

IDYA (IDEAYA Biosciences Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/11/2026

Comprehensive metric breakdowns and analytics for ideayabio.com (IDYA)

- stock price and consensus target price:

Stock Quotes IDEAYA Bio|IDYA - Average Forecast Price

- company stock capitalization data:

Market Valuation IDEAYA Corp|IDYA - Value Adjusted for Debt and Cash

- business book valuation details:

Accounting Value per Share IDEAYA Biosciences|IDYA - Total Net Assets|Market Capitalization to Book Value Ratio ideayabio.com|IDYA - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

IDYA - Company Net Income|Projected Future Earnings IDEAYA Biosciences|IDYA - Price to Earnings Multiple|Projected Price to Earnings IDEAYA Biosciences|IDYA - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio IDEAYA Corp|IDYA - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) IDEAYA Biosciences|IDYA - Earnings per share for the trailing year|Quarterly EPS earnings growth ideayabio.com|IDYA - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year IDEAYA Biosciences

Basic company analysis:IDEAYA Bio IDYA

For synthetic lethality leader IDEAYA Biosciences (IDYA), this ratio is critical when assessing business value considering debt load and strategic investments in its precision medicine platform. By analyzing the company's current EV/EBITDA trend, an investor compares the total enterprise value (market capitalization and debt) with its operating profitability, which helps identify whether the shares are overvalued or undervalued relative to actual cash flow.

Competitor analysis

Genmab US - Enterprise Value to EBITDA Ratio|Exelixis Inc. (EXEL) - Company Value to EBITDA|NUVL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KYMR (kymeratx.com)|ELVN (Enliven Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|ORIC: Enterprise Value to Operating Income Before Depreciation Ratio|RLAY (Relay Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Nurix Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Enterprise Value to EBITDA Multiple Cullinan Oncology|Immuneering Inc. - EV/EBITDA Multiple|Company Value to EBITDA C4 Therapeutics Corp|BDTX (Black Diamond) - Enterprise Value to EBITDA Ratio|RPTX: Enterprise Value to Operating Income Before Depreciation Ratio|PMVP (PMV Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Karyopharm KPTI|EV/EBITDA Multiple PPCB|Cyclacel - Enterprise Value to Operating Income Before Depreciation|Aadi Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ALRN|BPMC: Enterprise Value to EBITDA Ratio|GlycoMimetics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|SWTX: EV/EBITDA Multiple